Get the Stockscreener App
489.98
0.69%
3.37
After Hours:
489.98
Idexx Laboratories Inc stock is traded at $489.98, with a volume of 802.22K.
It is up +0.69% in the last 24 hours and up +35.71% over the past month.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
See More
Previous Close:
$486.61
Open:
$487.14
24h Volume:
802.22K
Relative Volume:
0.97
Market Cap:
$37.91B
Revenue:
$3.93B
Net Income/Loss:
$894.97M
P/E Ratio:
45.28
EPS:
10.82
Net Cash Flow:
$837.70M
1W Performance:
+3.95%
1M Performance:
+35.71%
6M Performance:
+13.09%
1Y Performance:
+0.60%
1-Day Range:
$485.40
$495.56
1-Week Range:
$465.00
$495.56
52-Week Range:
$356.14
$548.88
Idexx Laboratories Inc Stock (IDXX) Company Profile
Name
Idexx Laboratories Inc
Sector
Industry
Phone
(207) 556-0300
Address
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
489.98 | 37.91B | 3.93B | 894.97M | 837.70M | 10.82 |
|
TMO
Thermo Fisher Scientific Inc
|
410.78 | 158.51B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
194.82 | 140.78B | 23.82B | 3.77B | 4.90B | 5.15 |
|
A
Agilent Technologies Inc
|
108.70 | 31.23B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
153.29 | 26.31B | 15.41B | 1.37B | 2.11B | 7.50 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | BTIG Research | Buy |
| Jan-30-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Dec-04-23 | Upgrade | Cleveland Research | Neutral → Buy |
| Aug-02-23 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Jul-25-22 | Downgrade | Stifel | Buy → Hold |
| Jul-21-22 | Upgrade | Goldman | Neutral → Buy |
| Jul-12-22 | Initiated | Piper Sandler | Overweight |
| May-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-08-22 | Initiated | Atlantic Equities | Overweight |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-17-21 | Initiated | Barclays | Overweight |
| Sep-09-19 | Initiated | Goldman | Neutral |
| May-23-19 | Initiated | Guggenheim | Buy |
| Nov-02-18 | Reiterated | BofA/Merrill | Buy |
| May-07-18 | Reiterated | Stifel | Buy |
| Jan-16-18 | Initiated | Piper Jaffray | Overweight |
| Aug-23-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-28-17 | Upgrade | CL King | Neutral → Buy |
| Feb-03-17 | Downgrade | Feltl & Co. | Hold → Sell |
| Sep-29-16 | Resumed | BofA/Merrill | Neutral |
| Aug-16-16 | Reiterated | Stifel | Buy |
| Aug-03-16 | Upgrade | Northcoast | Sell → Neutral |
| Jul-20-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-19-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-01-16 | Initiated | CL King | Neutral |
| Mar-21-16 | Reiterated | Stifel | Buy |
| Feb-04-16 | Initiated | Credit Suisse | Outperform |
| Oct-29-15 | Reiterated | Stifel | Buy |
| Aug-28-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-13-15 | Reiterated | Stifel | Buy |
| Jul-23-15 | Reiterated | Canaccord Genuity | Buy |
View All
Idexx Laboratories Inc Stock (IDXX) Latest News
Here’s Why Baron Focused Growth Fund Invested in IDEXX Laboratories (IDXX) - Yahoo Finance
IDEXX Laboratories (IDXX) Target Price Raised by Morgan Stanley | IDXX Stock News - GuruFocus
BTIG Raises Price Target on IDEXX Laboratories to $545 From $530, Maintains Buy Rating - marketscreener.com
Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $558 From $548, Maintains Overweight Rating - marketscreener.com
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q1 2025 Earnings Call Transcript - Insider Monkey
IDEXX Laboratories [NasdaqGS:IDXX] Raises 2025 Guidance and Reports Q1 Growth in Revenue and EPS - Yahoo Finance
Leerink Partners Adjusts IDEXX Laboratories Price Target to $515 From $500 - marketscreener.com
IDEXX Laboratories Announces First Quarter Results | IDXX Stock News - GuruFocus
IDEXX Laboratories (IDXX) Surpasses Q1 Expectations with Robust Earnings - GuruFocus
IDEXX Laboratories Inc (IDXX) Q1 2025 Earnings Call Highlights: Strong Organic Growth Amid ... - Yahoo Finance
IDEXX Laboratories Inc (IDXX) Q1 2025 Earnings Call Highlights: Strong Organic Growth Amid Market Challenges - GuruFocus
IDEXX Laboratories Reports Strong Q1 2025 Results - TipRanks
IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) CEO Compensation Looks Acceptable To Us And Here's Why - simplywall.st
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Lab jumps after Q1 beat and guidance raise - MSN
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts - Yahoo Finance
Stifel Adjusts Price Target for Idexx Laboratories (IDXX) Following Q1 Results | IDXX Stock News - GuruFocus
IDEXX Laboratories (IDXX) Surges After Lifting 2025 Outlook on F - GuruFocus
IDEXX Laboratories stock jumps on Q1 beat (IDXX:NASDAQ) - Seeking Alpha
IDEXX Laboratories (IDXX) Reports Strong Start to 2025 with Reve - GuruFocus
IDEXX Laboratories Ups Profit Forecast Thanks To Pet Care Demand - Finimize
Earnings call transcript: IDEXX Labs Q1 2025 EPS beats forecast, stock surges - Investing.com
IDXX Q1 Earnings Beat, FY25 View Raised, Stock Up in Pre-Market - TradingView
IDEXX beats the Street on Q1 results, raises 2025 outlook - Mainebiz
Does IDEXX Laboratories (NASDAQ:IDXX) Deserve A Spot On Your Watchlist? - Yahoo Finance
IDEXX Laboratories raises annual profit view on strong demand for its pet diagnostics - marketscreener.com
IDEXX (IDXX) Reports Q1 Revenue Exceeding Expectations | IDXX St - GuruFocus
IDEXX Laboratories Q1 Earnings, Revenue Increase; 2025 Outlook Raised - marketscreener.com
Idexx Laboratories (IDXX) Beats Q1 Earnings Estimates - Yahoo Finance
Idexx: Q1 Earnings Snapshot - MySA
IDEXX Laboratories Q1 2025 Earnings: EPS of $2.96 Beats Estimate - GuruFocus
IDEXX Laboratories Inc Q1 Profit Advances, Beats Estimates - Nasdaq
IDEXX LABS Earnings Results: $IDXX Reports Quarterly Earnings - Nasdaq
Earnings Flash (IDXX) IDEXX Laboratories Posts Q1 EPS $2.96, vs. FactSet Est of $2.85 - marketscreener.com
IDEXX Labs earnings beat by $0.05, revenue fell short of estimates - Investing.com South Africa
IDEXX Laboratories Announces First Quarter Results - TradingView
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss? - TradingView
Here's How Much $100 Invested In IDEXX Laboratories 10 Years Ago Would Be Worth Today - Benzinga
Press Release Distribution & PR Platform - ACCESS Newswire
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term - Yahoo
Animal Health Diagnosis Market Is Booming So Rapidly with IDEXX Laboratories, Zoetis - openPR.com
Earnings Preview: What to Expect From IDEXX Laboratories' Report - MSN
Earnings Preview: What To Expect From IDEXX Laboratories' Report - Barchart.com
Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth US$427 Based On Its Intrinsic Value? - simplywall.st
Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
'The Nite Show with Danny Cashman' is Coming to an End - 94.9 HOM
A Look Into IDEXX Laboratories Inc's Price Over Earnings - Benzinga
Idexx Laboratories Inc Stock (IDXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):